Ergic1, encoding a putative transmembrane protein at the ER-Golgi interface, may be involved in protein trafficking between the endoplasmic reticulum and Golgi [2]. Its function is crucial for normal physiological processes, and disruption could potentially impact multiple cellular functions related to protein transport and processing.

Mutations in Ergic1 have been linked to arthrogryposis. Homozygous missense variants and a homozygous 22.6 Kb deletion encompassing the promoter and first exon of Ergic1 have been found in patients with relatively mild non-syndromic arthrogryposis, validating its pathogenic role in congenital arthrogryposis [1,2]. In addition, ERGIC1 expression was decreased in gastric cancer initiation, and overexpression in gastric cancer cell lines inhibited cell proliferation and enhanced apoptosis, suggesting an inhibitory role in gastric cancer [3,4]. In prostate cancer, ERGIC1 silencing regulated the proliferation of ERG oncogene-positive prostate cancer cells, indicating it as a potential drug target in this subgroup [5]. Also, ERGIC1 has been identified as a hub gene in COVID-19-related myocarditis, with potential drugs targeting it [6].

In conclusion, Ergic1 plays significant roles in multiple biological processes and disease conditions. Its involvement in arthrogryposis, gastric cancer, prostate cancer, and COVID-19-related myocarditis, as revealed through patient-based studies, highlights its importance in understanding these diseases. Further research on Ergic1 may provide new insights into disease mechanisms and potential therapeutic targets.